XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities Aug 13, 2024 7:30am EDT
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher Jun 12, 2024 7:30am EDT
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ May 14, 2024 7:30am EDT
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities May 09, 2024 7:30am EDT
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Apr 30, 2024 7:30am EDT
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) Apr 25, 2024 7:30am EDT
